Invention Grant
US08383605B2 Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
有权
与抗代谢药物组合使用的烷基磷酰胆碱治疗人类和哺乳动物的良性和恶性肿瘤
- Patent Title: Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
- Patent Title (中): 与抗代谢药物组合使用的烷基磷酰胆碱治疗人类和哺乳动物的良性和恶性肿瘤
-
Application No.: US12798267Application Date: 2010-03-31
-
Publication No.: US08383605B2Publication Date: 2013-02-26
- Inventor: Jürgen Engel , Eckhard Günther , Herbert Sindermann , Babette Aicher
- Applicant: Jürgen Engel , Eckhard Günther , Herbert Sindermann , Babette Aicher
- Applicant Address: DE Frankfurt
- Assignee: AEterna Zentaris GmbH
- Current Assignee: AEterna Zentaris GmbH
- Current Assignee Address: DE Frankfurt
- Agency: Goodwin Procter LLP
- Main IPC: A61K31/70
- IPC: A61K31/70 ; A61K31/685 ; C07C9/02
Abstract:
The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II. A particularly effective treatment includes administering a combination of perifosine and capecitabine.
Public/Granted literature
Information query
